Navigation Links
Quanterix Appoints Paul Chapman as President and Chief Executive Officer
Date:7/20/2012

LEXINGTON, Mass., July 20, 2012 /PRNewswire/ -- Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it has appointed Paul Chapman as its new President and Chief Executive Officer.  Mr. Chapman joins the company at a pivotal time, as it moves from development to commercialization of its revolutionary digital ELISA platform that improves conventional immunoassay sensitivity 1000-fold.

"Quanterix's Simoa technology has the potential to dramatically change the world of biomarker research and clinical diagnostics," says Chapman.   "I am very excited to work with the exceptional team at Quanterix to make that potential a reality in the near future."

Prior to joining Quanterix, Mr. Chapman was Vice President of the BioPharm Process Solutions business at EMD Millipore where he was responsible for the Marketing and R&D teams in the $800 million business.   Prior to joining Millipore, he was the Vice President, Hospital Solutions for Roche Near Patient Testing in Austria, where he held P&L responsibility for Roche's decentralized Cardiac, Blood Gas / Electrolyte and Hospital Glucose businesses.  Mr. Chapman was also the International Business Development Manager at Roche Molecular Diagnostics for blood screening and, prior to that, held an array of sales and marketing positions at Roche Diagnostics Canada (where he began his career in 1993) focused primarily in the Molecular Diagnostics field.  Mr Chapman has a B.Sc. in Microbiology from the University of Western Ontario, a B.Sc (hons) in Immunology from the University of Guelph Ontario, and graduated from the Marketing Management Program (MMP) from the Richard Ivy School of Business.

"Paul is a visionary leader with a strong track record in several businesses and I have great confidence that he will make Quanterix a huge success," says Martin Madaus, Executive Chairman of the Board of Directors. "His background and capabilities to bring new technologies to market successfully make him uniquely qualified for Quanterix."  

Dr. Martin Madaus, who was previously CEO and Executive Chairman of the Board of Directors, will continue at Quanterix as the Executive Chairman, while Mr. Chapman takes the reins of the company's operations as President and Chief Executive Officer to prepare the organization for the launch of its first product in 2013. 

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
2. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
3. C3i Appoints Jonathan Song to Business Development Executive in Asia
4. Organovo Holdings Appoints James T. Glover to Board of Directors
5. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
6. ReShape Medical Appoints Robert E. Grant to Board of Directors
7. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
8. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
9. Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
10. GenVec Appoints Cynthia Collins as President and CEO
11. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... WASHINGTON D.C. , May 4, 2016 /PRNewswire/ ... its member companies concluded a series of free ... training in global requirements for Good ... part of quality assurance which ensures that products are ... by the marketing authorization (MA) or product specification. Only ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... NEW YORK (PRWEB) , ... May 05, 2016 , ... ... and swimming safety – today announced a new partnership to reach nearly 1 million ... can happen in an instant and is the leading cause of accidental death in ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun ... talk highlighting the organization’s successful Care Transitions program at the 9th ... was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” ...
(Date:5/5/2016)... ... , ... The 2016 Nike Soccer Camp will be directed by the 2015 ... Together they bring their winning Vandals coaching philosophy to young athletes. Programs are offered ... high school players. Session dates are as follows: , Youth Day Camp – July ...
(Date:5/5/2016)... ... May 05, 2016 , ... Talent Tech Labs (TTL) is pleased ... of National Nurses Week (May 6-12). Currently, HireNurses is a job listing ... into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality ...
Breaking Medicine News(10 mins):